Indaptus Therapeutics, Inc. (NASDAQ: INDP)

Indaptus Therapeutics, Inc., a clinical biotechnology company, is making strides in the development of a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. The company's approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses can be achieved by using intact bacteria, containing multiple pathogen-associated molecular patterns (PAMPs), which have been attenuated to allow safe intravenous administration. This innovative method has led to broad anti-tumor and anti-viral activity in preclinical models, demonstrating durable anti-tumor response synergy with five different classes of existing agents, including checkpoint therapy, targeted antibody therapy, and low-dose chemotherapy.

Indaptus Therapeutics' patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced intravenous toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. The company's primary focus is on the development of its lead product candidate, Decoy20, for patients with advanced solid tumors where currently approved therapies have failed. Decoy20 has undergone successful current Good Manufacturing Practice (cGMP) manufacturing and has completed Investigational New Drug (IND)-enabling studies.

The company's technology has produced single agent activity and/or combination therapy-based durable responses in lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as activity against hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infection in standard preclinical models. Indaptus Therapeutics' target indications include, but are not limited to, colorectal, hepatocellular (± HBV), bladder, cervical, and pancreatic carcinoma, which account for a significant percentage of yearly cancer cases and deaths worldwide.

In a highly regulated industry, Indaptus Therapeutics must comply with FDA regulations, including the submission of an IND, which must become effective before human clinical studies may begin, and the performance of adequate and well-controlled human clinical studies in accordance with Good Clinical Practice (GCP) to establish the safety and efficacy of its product candidates. The company's product candidates, including Decoy20, are subject to the FDA's rigorous approval process, which includes preclinical testing, clinical trials, and post-marketing surveillance.

Indaptus Therapeutics' competitive advantages include its bacteria containing multiple constituents, capable of priming or activating many of the cellular components of both innate and adaptive immunity, but have been attenuated by a patented process to reduce the potential for over-stimulation of the immune system and consequential induction of undesirable autoimmune reactions. Additionally, the company's products can be manufactured by a highly cost-efficient process, potentially providing accelerated patient access in both developed and developing geographical regions.

The company's key competitors include larger and better-funded biopharmaceutical, biotechnology, and therapeutics companies, such as Amgen, Inc., AstraZeneca plc, BMS, Genentech, Inc., GlaxoSmithKline PLC, Merck & Co., Inc., Novartis AG, Pfizer Inc., Roche Holding Ltd, and Sanofi S.A. However, Indaptus Therapeutics believes that its technology and scientific resources provide it with certain competitive advantages.

Indaptus Therapeutics' success will depend, at least in part, on its ability to protect its proprietary technology and intellectual property, and to operate without infringing or violating the proprietary rights of others. The company relies on a combination of patent, trademark, trade secret, and copyright laws, know-how, intellectual property licenses, and other contractual rights to protect its proprietary technology and intellectual property.